Who are Blinded clopidogrel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aspirin or thienopyridine, Clopidogrel treatment, Ticagrelor loading dose, Aspirin + Clopidogrel + Rivaroxaban, Aspirin and thienopyridine, clopidogrel and metoprolol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/blinded-clopidogrel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Blinded clopidogrel — Competitive Intelligence Brief

Blinded clopidogrel (Blinded clopidogrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agents. Area: Metabolic.

marketed Antiplatelet agents P2Y12 receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Blinded clopidogrel (Blinded clopidogrel) — VA Office of Research and Development.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Blinded clopidogrel TARGET	Blinded clopidogrel	VA Office of Research and Development	marketed	Antiplatelet agents	P2Y12 receptor
Aspirin or thienopyridine	Aspirin or thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Antiplatelet agents	COX-1 (aspirin); P2Y12 receptor (thienopyridines)
Clopidogrel treatment	Clopidogrel treatment	VA Office of Research and Development	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Ticagrelor loading dose	Ticagrelor loading dose	Icahn School of Medicine at Mount Sinai	marketed	P2Y12 platelet receptor antagonist	P2Y12 receptor
Aspirin + Clopidogrel + Rivaroxaban	Aspirin + Clopidogrel + Rivaroxaban	China National Center for Cardiovascular Diseases	marketed	Antiplatelet agent + Anticoagulant combination	Platelet cyclooxygenase, P2Y12 receptor, Factor Xa
Aspirin and thienopyridine	Aspirin and thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Dual antiplatelet agent combination	COX-1 (aspirin); P2Y12 receptor (thienopyridine)
clopidogrel and metoprolol	clopidogrel and metoprolol	University of Oxford	marketed	Antiplatelet agent combined with beta-blocker	P2Y12 receptor (clopidogrel); beta-1 adrenergic receptor (metoprolol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agents class)

Associations for Establishment of Evidence in Interventions · 1 drug in this class
University Hospital, Angers · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Blinded clopidogrel — Competitive Intelligence Brief. https://druglandscape.com/ci/blinded-clopidogrel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab